PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

• Main Authors: Thura M., Al-Aidaroos A.Q., Gupta A., Chee C.E., Lee S.C., Hui K.M., Li J., Guan Y.K., Yong W.P., So J., Chng W.J., Ng C.H., Zhou J., Wang L.Z., Yuen J.S.P., Ho H.S.S., Yi S.M., Chiong E., Choo S.P., Ngeow J., Ng M.C.H., Chua C., Yeo E.S.A., Tan I.B.H., Sng J.X.E., Tan N.Y.Z., Thiery J.P., Goh B.C., Zeng Q.
• Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
• Format: Article
• Published: Nature Publishing Group 2020
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/175940
• Institution: National University of Singapore

10.1038/s41467-019-10127-x